The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Like tens of thousands of Massachusetts residents, community college professor Carolyn McGrath has been paying for medicine ...

Teladoc stock has declined significantly, from a high of $14 per share in February to $7 per share. Read why I downgrade TDOC ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls’ ...

Scholar Rock Holding Corporation's apitegromab shows promise for SMA treatment, aims for 2025 launch. Click for my updated ...

Pfizer (PFE) stock declined 1.5% in the pre-market trading session today, after the company discontinued the development of its experimental ...

Novo Nordisk (NYSE:NVO) is focused on researching, developing, manufacturing, and distributing pharmaceutical products. For ...

Eli Lily's GLP-1 competitor Mounjaro/Zepbound ... the true challenges facing seniors and Medicare," industry group PhRMA said in a statement. “Over half the medicines selected for price setting ...

Tirzepatide-based medicines Mounjaro for diabetes and Zepbound for obesity have led ... was volatile in the first half of the year due to challenges fulfilling high demand, our progress on supply ...

Amid inflation, tariffs, shifting consumer behaviors and supply chain upheavals, landlords and retailers are turning ...

Artificial intelligence (AI) is redefining how businesses operate, forcing a rethink of traditional SaaS pricing models. The ...